First-In-Human Assessment of LB-100, Lixte Biotechnology–s Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research
Commercial & Investment Banking, Picture Gallery Wednesday, January 4th, 2017
EAST SETAUKET, NY — (Marketwired) — 01/04/17 — Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced the online of Phase 1 results of its novel anti-cancer compound in Clinical Cancer Research, entitled "Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors." ()John S. Kovach, M.D., Founder and President of Lixte said "We are encouraged that ten (46.7%) of twenty-one patients receiving at
